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REVIEW CURRENTOPINION Scaling up HIV self-testing in sub-Saharan Africa:
a review of technology, policy and evidencewww.co-infectiousdiseases.coma a,b a,cPitchaya P. Indravudh , Augustine T. Choko , and Elizabeth L. CorbettPurpose of review
HIV self-testing (HIVST) can provide complementary coverage to existing HIV testing services and improve
knowledge of status among HIV-infected individuals. This review summarizes the current technology, policy
and evidence landscape in sub-Saharan Africa and priorities within a rapidly evolving field.
Recent findings
HIVST is moving towards scaled implementation, with the release of WHO guidelines, WHO
prequalification of the first HIVST product, price reductions of HIVST products and a growing product
pipeline. Multicountry evidence from southern and eastern Africa confirms high feasibility, acceptability
and accuracy across many delivery models and populations, with minimal harms. Evidence on the
effectiveness of HIVST on increased testing coverage is strong, while evidence on demand generation for
follow-on HIV prevention and treatment services and cost-effective delivery is emerging. Despite these
developments, HIVST delivery remains limited outside of pilot implementation.
Summary
Important technology gaps include increasing availability of more sensitive HIVST products in low and
middle-income countries. Regulatory and postmarket surveillance systems for HIVST also require further
development. Randomized trials evaluating the effectiveness and cost-effectiveness under multiple
distribution models, including unrestricted delivery and with a focus on linkage to HIV prevention and
treatment, remain priorities. Diversification of studies from west and central Africa and around blood-based
products should be addressed.
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Adult HIV incidence has largely remained static in
sub-Saharan Africa, with an estimated 25.5 million
people living with HIV (PLHIV) and 1.3 million
new infections annually [1]. Despite increased avail-
ability of provider-initiated and community-based
HIV testing services (HTS), only 76% of PLHIV in
eastern and southern Africa and 42% of PLHIV
in western and central Africa are aware of their
serostatus [2].
HIV self-testing (HIVST), a process in which
individuals collect their own specimen, perform
the test and interpret the results, can provide com-
plementary coverage to standard HTS and reach
undiagnosed PLHIV and individuals with high
ongoing HIV risk [3]. Reactive results need to be
confirmed through additional testing by a trained
provider, whereas nonreactive results should
prompt linkage to prevention services, including
voluntary medical male circumcision (VMMC)
and preexposure prophylaxis (PrEP) if indicated [3].The field of HIVST is rapidly evolving. This
review summarizes the current technology, policy
and evidence landscape for HIVST in sub-Saharan
Africa, with priorities for scaled implementation
outlined. Current developments in technology
and policy were assessed through HIVST.org, a rela-
tional map hosted byWHO [4]. Recent and ongoingVolume 31  Number 1  February 2018
KEY POINTS
 HIVST is moving towards scaled implementation, with
the release of WHO guidelines, WHO prequalification
of the first HIVST product, price reductions of HIVST
products and a growing product pipeline.
 Multicountry evidence from southern and eastern Africa
confirms high feasibility, acceptability and accuracy
across many delivery models and populations,
including adolescents, men and female sex workers,
with reassuringly minimal harms.
 Randomized trials evaluating the effectiveness and cost-
effectiveness under multiple distribution models,
including unrestricted delivery and with a focus on
linkage to HIV prevention and treatment, remain
priorities.
 Diversification of studies from west and central Africa
and around blood-based products should be addressed.
Scaling up HIV self-testing in sub-Saharan Africa Indravudh et al.observational studies and trials were identified
through PubMed, ClinicalTrials.gov, ISRCTN and
the Pan African Clinical Trials Registry. The review
was conducted through September 2017.TECHNOLOGY UPDATE
Products for HIV self-testing available in sub-
Saharan Africa are listed in Table 1. Products use
either oral-fluid or finger-prick blood samples and
take between 5 and 7 steps and 1 and 45 minutes to
provide results [5]. Ideal products should be easy to
use and interpret for optimized accuracy, with clear
instructions-for-use (IFU) that are available in localTable 1. HIV rapid diagnostic tests for self-testing available in su
Name (generation), Regulatory
manufacturer Specimen approvals
Amethyst HIV 1&2 Test Kit, MYSP
Nigeria Ltd.
Oral fluid NAFDAC
Atomo HIV Self-Test (3rd), Atomo
Diagostics
Blood CE marked
autotest VIH (2nd), AAZ-LMB Blood CE marked
BioSURE HIV Self-Test (2nd), BioSure
Ltd.
Blood CE marked
INSTI HIV Self-Test (3rd), bioLytical
Laboratories Inc.
Blood CE mark pend
modified LM
OraQuick In-Home HIV Test (2nd),
OraSure Technologies Inc.
Oral fluid FDA
OraQuick HIV Self-Test (2nd),
OraSure Technologies Inc.
Oral fluid WHO PQ
Adapted from the WHO/Unitaid Market and Technology Landscape: HIV Rapid Dia
CE, European Conformity; FDA, U.S. Food and Drug Administration; LMICs, low-inc
Food and Drug Administration Control; PQ, prequalified; SSA, Sub-Saharan Africa.
0951-7375 Copyright  2018 The Author(s). Published by Wolters Kluwelanguages and understandable at low literacy and
education levels [6]. Most HIVST products in devel-
opment are repurposed professional-use rapid diag-
nostic tests (RDTs) [5], with innovation limited to
packaging and IFU modifications and single-use
parts (e.g. pipette, lancet, etc.) [7]. Most commer-
cially available RDTs for self-testing are second-
generation assays, which detect immunoglobin G
antibodies but not immunoglobin M antibodies
(third generation) nor viral antigens (fourth genera-
tion) and nucleic acids. Compared to later genera-
tions, second-generation tests require a longer
window period of 28 days between infection and
test positivity [5].
In low and middle-income countries (LMIC),
price per self-test currently ranges from US$2 to 3
for public sector procurement and US$8–16 retail in
the private sector [5]. In 2017, unit costs for Ora-
Quick HIV Self-Test were reduced under a temporary
donor agreement, enabling government or charita-
ble purchase for US$2 in 50 LMICs [8]. This agree-
ment has important implications for HIVST market
development, with potential for price reductions to
increase demand and facilitate a competitivemarket
for HIVST. Alternatively, it could discourage man-
ufacturers from investment in innovations that
improve usability and precision but increase costs,
underpinning the need for incentives to further
product development [7].POLICY UPDATE
International and national policy to guide HIVST
implementation, as well as regulatory and quality
assurance systems, are integral to scale-up in sub-b-Saharan Africa
Private sector Pricing in LMIC (US$)
availability in SSA Ex-works Retail
Nigeria $16
Kenya and
South Africa
$3, based on
volume
$13.40
$5
ing for
IC product
Kenya $3 $8–10
Kenya and
South Africa
$2 for 50
LMIC
$9.50
gnostic Tests for Self-Testing.
ome and middle-income countries; NAFDAC, Nigeria National Agency for
r Health, Inc. www.co-infectiousdiseases.com 15
HIV infections and AIDSSaharan Africa. In 2016, WHO released guidelines
recommending HIVST based on evidence of
increased uptake and frequency of testing, especially
among underserved and high-risk populations [3].
This prompted a shift in national policies suppor-
tive of HIVST, from four countries in 2015 to 40
countries at the time of the review, of which
15 countries are from sub-Saharan Africa (Fig. 1)
[9]. Despite the changing policy environment,
few countries are implementing HIVST at scale
and only Kenya has released full operational guide-
lines [10].
Regional and national regulatory systems for
HIVST are also generally poorly developed in sub-
Saharan Africa, with unregulated and low-quality
products available for purchase in certain markets
[11]. To inform procurement decisions, sub-Saharan
African countries tend to rely on approvals issued
from founding members of the Global Harmoniza-
tion Task Force or WHO [5], which prequalified its
first HIVST product for LMICs in 2017 [12].
Approved products are also now available through
limited pharmacies and retailers in Kenya and South
Africa [13,14]. However, given the numerous poten-
tial outlets for HIVST through the private sector,
countries will need to reassess their regulatoryFIGURE 1. Policy map of HIV self-testing (HIVST) in sub-Saharan
16 www.co-infectiousdiseases.comand postmarket surveillance systems to ensure
adequate consumer protection from ineffective
devices, without presenting undue barriers to bona
fide manufacturers.REVIEW OF EVIDENCE
Readiness and preferences for HIV
self-testing
Successful implementation of HIVST hinges on both
provider readiness to deliver HIVST and public
demand once HIVST services have been established.
Early studies in sub-Saharan Africa reported high
interest in HIVST among the general population
[15–17], couples [18], high-risk populations [19],
healthcare providers [20–22] and policy stakehold-
ers [23,24]. Recent evidence confirms high readiness
to self-test among a wider range of populations
[25,26
&
,27
&
,28–34,35
&&
,36
&&
,37,38], notably men
[26
&
,32], young people [27
&
,33,36
&&
], serodiscordant
couples [35
&&
], and sex workers and their partners
[25,30] (Table 2). Principal motivations for self-test-
ing include convenience and associated time
and cost savings; control over the testing process;
privacy and confidentiality; and ease-of-use andAfrica.
Volume 31  Number 1  February 2018
Scaling up HIV self-testing in sub-Saharan Africa Indravudh et al.painlessness of the oral fluid-based self-test [17,18,
21–25,26
&
,27
&
,28,30–32,34,35
&&
,37,38]. Nearly, all
of these studies evaluated oral fluid tests, although
two South African studies showed high acceptability
of blood-based products [36
&&
,38].
Specific values and preferences for HIVST varied
by population group. In Kenya, there was high
interest among the general population for fee-
based, pharmacy models because of enhanced
accessibility [34]. Alternatively, individuals who
valued access to professionalized care preferred to
obtain HIVST kits from health facilities [25,31].
Young people in Malawi and Zambia preferred
low-cost, home delivery and valued HIVST for
providing greater discretion around their sexual
debut [27
&
]. Men expressed interest in distribution
through lodges and bars because of flexible service
hours amid their work obligations [25]. Secondary
distribution of self-tests to male partners of antena-
tal care clients similarly provided added conve-
nience and privacy compared to clinic-based
couples testing, whereinmale attendancewas often
stigmatized [26
&
]. Sex workers valued HIVST as a
way to demonstrate trust to primary partners and
inform sexual decision-making with commercial
sex clients [30], whereas HIV-uninfected individu-
als on PrEP found that HIVST reduced anxiety in
between scheduled testing at clinics [35
&&
]. Willing-
ness to purchase HIVST kits varied across studies
(Table 2) [19,22,24,25,27
&
,28, 29,33,34,38], with
low ability to pay reported among women and
young people [27
&
,29].
Commonly reported concerns included the pos-
sibility for coercive testing and inability of individ-
uals to self-test accurately, psychologically cope
with reactive results and successfully link to confir-
matory testing and care [17,20,23–25,26
&
,27
&
,28,
31,34,37,38]. User-suggested solutions to tackle
potential adverse effects included clear, locally
translated IFUs, coupled with development of effec-
tive training and educational materials for providers
and accessible in-person and hotline-based support
for self-testers [25,27
&
,31,33,37,38]. A recent study
among Malawian men found that time-limited
behavioral motivators, specifically financial incen-
tives (US$3 and $10) and phone call reminders, were
also acceptable to facilitate linkage to prevention
and care [26
&
].Performance and usability of HIV self-testing
The public health impact of HIVST is contingent on
user ability to self-test and confidence in the results
to access further HIV services. Blood-based self-tests
have generally performed higher than oral fluid-
based self-tests, with sensitivity of 96.2-100% versus0951-7375 Copyright  2018 The Author(s). Published by Wolters Kluwe80-100% and specificity of 99.5-100% versus 95.1-
100%, but have rarely been evaluated in sub-
Saharan Africa [3]. Oral fluid-based self-tests have
achieved good sensitivity (93.6–100%) and specific-
ity (99.1–100%) [15,16,19,39] by rural and urban
Africans with a demonstration or provider supervi-
sion. In a recent blood-based study in South Africa,
96.4% of 224 participants correctly performed the
self-test and interpreted the results under direct
assistance [36
&&
]. Studies evaluating unassisted oral
fluid-based self-tests have attained sensitivity of
66.7–90.0% and specificity of 95.2–100% [19,22,
29]. Performance can depend on literacy level and
previous exposure to HIV testing, but can be opti-
mized through a demonstration-of-use [40–42].
Across studies, self-testing was often described as
easy, with few reported errors [6,15,19,20,22,29,
35
&&
,36
&&
,38,39,43]. Common missteps included
incorrect specimen collection and use of the buffer
solution and early reading or misinterpretation of
results [15,19,29,36
&&
,38,39]. Visual stability of self-
tests was inconsistent [44,45].Uptake of testing
Evidence on effective delivery models to increase
testing coverage among underserved populations
and testing frequency among high-risk populations
is critical for informing HIVST implementation.
A foundational study in Malawi reported that
community-based HIVST implementation led to
high uptake, particularly among women and ado-
lescents, in a high prevalence setting [16]. High
demand for HIVST has been subsequently shown
for pharmacy [34], facility [35
&&
,43] and partner-
delivered [46
&&
,47
&&
] models. A cohort study in
Kenya reported 98% uptake among 226 PrEP users
who received self-tests in between clinic testing
[35
&&
], showing high potential for HIVST to reduce
the burden of PrEP on users and providers oncemore
appropriate technologies for use among this popu-
lation are available.
High uptake was also achieved under secondary
distributionmodels. In a cohort of 280 pregnant and
postpartum women and sex workers, 75–91% of
participants across groups reported distributing kits
to their primary partner and 80% of sex workers also
distributed to commercial sex clients [47
&&
]. Among
partners of sex workers who received a reactive
result, 90% were clients, underpinning the ability
of HIVST to reach high-risk individuals. A sister
randomized controlled trial (n¼570) observed
higher coverage of self-reported partner testing
among pregnant and postpartum women when
given HIVST kits for secondary delivery compared
to partner invitation letters for clinic testing (90.8r Health, Inc. www.co-infectiousdiseases.com 17
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&&
]. Couples testing and
partner status disclosure were also more likely.
A number of ongoing randomized trials are
examining the effectiveness of HIVST on recent
and lifetime testing and positivity. The Self-Testing
Africa (STAR) Initiative is conducting trials of com-
munity-based delivery of self-tests among the gen-
eral population in Malawi (NCT02718274) and
Zambia (NCT02793804). Other notable trials are
evaluating direct and secondary distribution among
young women and sex workers (NCT02827240;
NCT02846402) and their partners (NCT03135067;
NCT03162965).Linkage to prevention and care
Scalable strategies for confirmation of HIV status
and continuation into the HIV prevention or care
cascade are needed to maximize individual and
public health benefits of HIVST. Studies have
described suboptimal linkage to care following
reactive results, though they were not designed
to assess nor statistically powered on linkage
[16,46
&&
,47
&&
,48]. In Malawi, linkage to care was
56.3% among community-based self-testers [16]. A
study in Kenya reported linkage to confirmatory
HTS was two of four among partners of pregnant
and postpartum women and 26 of 41 among part-
ners of sex workers [47
&&
]. In a Kenyan trial, two of
eight sexual partners linked to care in theHIVST arm
compared to three of four partners in the clinic
testing arm, as reported by proxy [46
&&
].
To enhance linkage after self-testing, an early
trial in Malawi found that the offer of home-based
confirmatory testing and antiretroviral therapy
(ART) initiation led to a three-fold increase in
population-level ART demand compared to referral
to facility-based care [48]. Interventions to facilitate
timely linkage to care are also being investigated in
Zimbabwe (PACTR201607001701788) and Malawi
(ISRCTN18421340), with preliminary results from
the latter study reporting significant benefits on
linkage to VMMC and ART using financial and
nonfinancial incentives [49].Cost and cost-effectiveness
Cost and cost-effectiveness estimates, which are
highly context-specific and dependent on the deliv-
ery model and prevalence of undiagnosed HIV,
are vital to inform national HIVST policy and
implementation. Mathematical modeling from
Zimbabwe suggests that HIVST has potential to be
cost-effective, contingent on delivery to high-
burden settings with low coverage of HIV testing;
reductions in delivery costs through less resource-0951-7375 Copyright  2018 The Author(s). Published by Wolters Kluweintensive implementation and cuts in HIVST unit
costs; and improvements in linkage to pre-
vention among HIV-negative individuals [50].
More epidemiological and economic data from
HIVST programs are needed to parameterize cost-
effectiveness estimates at a national level [51].
Ongoing trials mentioned in this review are
aiming to address this evidence gap. Cost data are
available from previous research in urban Malawi,
with evidence that community-based HIVST has
potential to be cost-effective in high-burden settings
[52]. The mean cost per individual tested through
community-based HIVST (US$8.78) was comparable
to facility-basedHTS (US$7.54) [53
&&
], but higher per
HIV-positive individual identified (US$97.50 versus
US$25.30-US$76.14). Self-testers incurred almost no
costs, compared to US$2.93 for facility testers, and
were diagnosed at earlier stages. A follow-on analysis
reported no differences in economic and quality of
life outcomes between self-testers and facility testers
one year after ART initiation [54]. Maintaining a
strong focus on implementation design tomaximize
cost-effectiveness will be important, especially as
the prevalence of undiagnosed HIV declines.Social and behavioral impact
Broader social and behavioral effects of HIVST, spe-
cifically around social harms and sexual risk-taking,
are important to evaluate and consider for scaled
implementation. Reassuringly, the incidence of seri-
ous social harms related to HIVST has been uni-
formly low, with no cases of suicide and few
reports of intimate partner violence to date
[16,18,35
&&
,46
&&
,47
&&
]. Coercive testing has been
reported by couples but highlights a complex
dynamic, where pressure to self-test is balanced by
the sense that primary partners are entitled to know
each other’s status [18]. Evidence on sexual risk-
taking is limited, with one study in Kenya finding
that a cohort of prepartum and postpartum women
and female sex workers were significantly less likely
to have sexual intercourse (18 versus 62%, P<0.01)
and more likely to use condoms (100 versus 44%,
P<0.01) if their partners received reactive compared
to nonreactive self-test results [47
&&
]. Ensuring
that self-testers are able to assess and avoid social
harms and understand risks of serosorting, as well
as developing systems for identification and man-
agement of social harms, are key considerations
for implementers.Research gaps and priorities
Recent evidence in sub-Saharan Africa has estab-
lished the feasibility, acceptability, accuracy andr Health, Inc. www.co-infectiousdiseases.com 21
Table 3. Progress and gaps toward scaling up HIV self-testing in sub-Saharan Africa
Progress Gaps
Technology Four BSTs and three OFSTs available in SSA (second
and third generation).
LMIC public sector prices at US$2–3, with price
reduction under charitable agreement. Private sector
prices at US$8–16
Limited product innovation beyond IFU and package
modification and single-use parts.
Limited availability of more sensitive HIVST products in LMICs
for high-risk populations.
High pricing for LMIC markets
Policy Release of WHO HIVST guidelines.
15 SSA countries with supportive HIVST policies
Absence of supportive HIVST policies in remaining countries,
especially in west and central Africa.
Most countries do not have complete HIVST operational
guidelines for scale-up
Regulation One OFST product approved by WHO PQ.
Two countries with international standard products
available in limited private sector channels
No BST product approved by WHO PQ.
Need for robust regulatory and postmarket surveillance
system given potential private sector outlets
Evidence High feasibility, acceptability and accuracy of HIVST
across a wide range of delivery models and
populations.
Minimal cases of social harm.
Emerging evidence on effectiveness of HIVST on
increased testing coverage and demand for follow-
on HIV services
More evidence needed on effectiveness and cost-effectiveness
under multiple delivery models, including unrestricted
distribution through public and private sectors and
strategies to minimize linkage delays.
Limited studies on BST and from west and central Africa
Secondary effects of HIVST, including on sexual risk-taking
and healthcare efficiency, are unknown
BST, blood-based self-testing; HIVST, HIV self-testing; LMIC, low-income and middle income; OFST, oral fluid-based self-testing; PQ, prequalification; SSA, sub-
Saharan Africa.
HIV infections and AIDSsafety of HIVST among target populations, but has
also revealed gaps that require immediate prioritiza-
tion (Table 3). Most studies have taken place in
southern and eastern Africa, with geographic diver-
sification from west and central Africa needed.
There is also limited evidence on blood-based
self-tests, which use less costly specimen collection
devices and are more sensitive compared to oral
fluid-based tests, and are therefore vital to facilitate
price reductions in HIVST products and for use
among high-risk populations. Research on how
implementers can improve HIVST performance by
optimizing IFUs and developing clear support mate-
rials through systematic assessment and adaptation
remains a priority across products.
The majority of current evidence comes from
small-scale observational studies, with findings
emerging from a number of ongoing randomized
trials and economic evaluations. Evidence on effec-
tive and affordable HIVST delivery models for
increasing testing coverage among underserved
populations and testing frequency among high-risk
populations are necessary for country decision-
making. Recent and ongoing trials have largely
evaluated community-based and partner-delivered
HIVST, revealing a gap among a wider range of
distribution models. With scale-up in mind, unre-
stricted distribution through public and private sec-
tors, as well as interventions to minimize linkage
delays among hard-to-reach populations, should be
evaluated. Studies should also ensure alignment of22 www.co-infectiousdiseases.comepidemiological and economic metrics with inputs
required for mathematical modeling to inform
national cost-effectiveness estimates, with the aim
of effectively and efficiently reaching undiagnosed
PLHIV. Finally, secondary effects of HIVST, includ-
ing sexual risk-taking and potential for efficiency
gains for providers through task-shifting, are rela-
tively unknown and require further investigation.CONCLUSION
HIVST is moving towards scaled implementation,
with the release of WHO guidelines, WHO prequali-
fication of the first HIVST product, price reductions
of HIVST products and a growing product pipeline.
Multicountry evidence from southern and eastern
Africa confirms high feasibility, acceptability and
accuracy across many delivery models and popula-
tions, including adolescents, men and female sex
workers, with reassuringlyminimal harms. Evidence
on the effectiveness of HIVST on increased testing
coverage is strong, while evidence on demand
generation for follow-on HIV prevention and treat-
ment services and cost-effective delivery is emerg-
ing. Despite these developments, HIVST delivery
remains limited outside of pilot implementation.
Important technology gaps include increasing
availability of more sensitive HIVST products in
LMICs. Regulatory and postmarket surveillance sys-
tems for HIVST also require further development.
Randomized trials evaluating the effectiveness andVolume 31  Number 1  February 2018
Scaling up HIV self-testing in sub-Saharan Africa Indravudh et al.cost-effectiveness under multiple distribution mod-
els, including unrestricted delivery and with a focus
on linkage toHIV prevention and treatment, remain
priorities. Diversification of studies from west and
central Africa and around blood-based products
should be addressed.Acknowledgements
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